• Clint Pecenka, Erin Sparrow, Daniel R Feikin, Padmini Srikantiah, Delese Mimi Darko, Eric Karikari-Boateng, Ranju Baral, Carla Vizzotti, Analia Rearte, Rose Jalang'o, Jessica A Fleming, Federico Martinón-Torres, and Ruth A Karron.
• Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA. Electronic address: cpecenka@path.org.
• Lancet. 2024 Sep 21; 404 (10458): 115711701157-1170.

AbstractThe search for safe and efficacious products to prevent severe respiratory syncytial virus (RSV) disease in young infants has lasted more than 60 years. In high-income and middle-income countries, two new products have been authorised: an RSV monoclonal antibody for administration to infants (nirsevimab) and an RSV prefusion F maternal vaccine (RSVpreF [Pfizer, Puurs, Belgium]) for administration to pregnant people. These products are not yet available in low-income and lower-middle-income countries, where most RSV deaths occur. Other papers in this Series describe the acute burden of RSV disease in young children, the effects of RSV infection in early childhood on long-term lung health, and the burden of RSV disease and disease prevention products in older adults. In this Series paper, we briefly review the efficacy, effectiveness, and safety of nirsevimab and RSVpreF maternal vaccine for protection of infants. We then explore potential regulatory, policy, and implementation pathways and provide case studies of intervention uptake in Spain and Argentina, and considerations for use in Kenya. We also explore the health economic evidence to inform product introduction decisions. With sufficient political will and affordable pricing, RSV disease prevention in infants can become a global reality.Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

36 keywords...

hide…